1339-93-1

Basic information

• Product Name: Digitalis
• Synonyms: (3beta,5beta,17alpha)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-> 4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-> 4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide; card-20(22)-enolide, 3-[[O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-> 4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-> 4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy]-14-hydroxy-, (3beta,5beta,17alpha)-; (3beta,5beta,17alpha)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide
• CAS NO: 1339-93-1
• Molecular Formula: C41H64O13
• Molecular Weight: 764.93906
• EINECS: 200-760-5
• Mol File: 1339-93-1.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 683.69°C (rough estimate)
• Flash Point: 269.5°C
• Appearance: /
• Density: 1.1509 (rough estimate)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.5940 (estimate)
• CAS DataBase Reference: Digitalis(CAS DataBase Reference)
• NIST Chemistry Reference: Digitalis(1339-93-1)
• EPA Substance Registry System: Digitalis(1339-93-1)

Safety Data

• Hazardous Substances Data: 1339-93-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26+,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1

Related news

Novel perspectives on two Digitalis (cas 1339-93-1) species: Phenolic profile, bioactivity, enzyme inhibition, and toxicological evaluation09/07/2019

The present study outlines the phenolic composition of methanolic extracts of Digitalis ferruginea and Digitalis lamarckii aerial parts and evaluates their biological activities. The quantification of phenolic compounds was carried out by HPLC–DAD analysis. Antioxidant properties were assessed ...detailed

Three seasonal comprehensive evaluation process of Digitalis (cas 1339-93-1) trojana Ivan’s phenolics09/05/2019

Digitalis trojana Ivan, a member of Digitalis genus, has highly bioactive properties due to efficient phenolics. These compounds have shown to convert into each other in a limited time. Seasonal fluctuations of this plant leaves have been studied during the summer season using the high performan...detailed

New knowledge about old drugs; a cardenolide type glycoside with cytotoxic effect and unusual secondary metabolites from Digitalis (cas 1339-93-1) grandiflora Miller09/03/2019

Phytochemical investigation of the aerial parts of Digitalis grandiflora Miller (Plantaginaceae) led to the isolation of an undescribed cardenolide type glycoside digigrandifloroside (1) along with five known compounds, rengyoside A (2), rengyoside B (3), cleroindicin A (4), salidroside (5), and...detailed

Cytotoxic phenylethanoid glycosides from Digitalis (cas 1339-93-1) davisiana Heywood: Evaluation of structure activity relationships and chemotaxonomical significance of isolated compounds09/02/2019

The phytochemical studies on the aerial parts of Digitalis davisiana Heywood led to the isolation of three undescribed phenylethanoid glycosides named as digidavisoside A (5), digidavisoside B (7), and davisoside (8), along with 9 known compounds, ferruginoside B (1), isolugrandoside (2), lugran...detailed

Alternans during fascicular ventricular tachycardia due to Digitalis (cas 1339-93-1) toxicity09/01/2019

This report describes a digitalis-induced regular fascicular ventricular tachycardia characterized by marked QRS alternans a manifestation not usually associated with this arrhythmia. The striking alternation of QRS configuration suggested alternating ventricular activation from either a single ...detailed

Effect of Digitalis (cas 1339-93-1) level on readmission and mortality rate among heart failure reduced ejection fraction patients08/31/2019

IntroductionDigitalis has been used for over 200 years to treat patients with heart failure, and evidence supports its use to improve clinical symptoms and quality of life, but not survival. The objective of this retrospective study was to evaluate the effects of digitalis on readmission and mor...detailed

Case ReportDigoxin-specific Fab and therapeutic plasma exchange for Digitalis (cas 1339-93-1) intoxication and renal failure08/30/2019

Treatment of chronic digitalis intoxication includes suspension of drug intake, which may be sufficient in case of mild manifestations, and supportive measures. Severe bradycardia requires the administration of atropine or isoproterenol; placement of a temporary pacemaker may be required in case...detailed